Company Profile: Boston Scientific Corporation (BSX)
BSX insider trades (13 months) →$43.50 −1.85% vs. previous close · Market cap $63.04B
Today's multi-factor rank: 430 of 461 · see the ranking
Market and Valuation
Price & Market
52-Week Range
Volume
Valuation Multiples
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Nov 2, 2026. The P/E is the price divided by that EPS.
Dividends
Valuation Context
P/E vs sector (indicative)
Loading historical OHLCV database...
Financial Statements TTM (Trailing 12 Months)
Income Statement
Margins
Per Share
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Nov 2, 2026. The P/E is the price divided by that EPS.
Balance Sheet & Liquidity
Cash Flows
Profitability
Historical Evolution (Last 4 Years)
Income Statement
Balance Sheet
Cash Flow
EPS and Earnings Per Share
Key EPS Metrics
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Nov 2, 2026. The P/E is the price divided by that EPS.
Growth and Margins
Per Share
Cash Flows (TTM)
EPS Surprise History - Last 4 Quarters
Actual vs. Analyst Estimates · Green = beat expectations · Red = missed
| Quarter | Period | Actual EPS | Estimated EPS | Difference | Surprise % | Currency |
|---|
Ownership Structure
Ownership Distribution
Shares & Short Interest
Governance Score (1=Best, 10=Worst)
Top Institutional Holders
Position Change: ▲ Increased · ▼ Reduced · = Unchanged
| Organization | Report Date | % Shares | No. Shares | Value (USD) | Change % |
|---|
Top Mutual Funds
Position Change: ▲ Increased ▼ Decreased = Unchanged
| Fund | Report Date | % Shares | No. Shares | Value (USD) | Change % |
|---|
Recent Insider Trades
| Executive / Insider | Title | Date | Action | Shares |
|---|
Options Chain
CALLS
| Strike | Last | Bid | Ask | Vol. | O.I. | IV |
|---|
PUTS
| Strike | Last | Bid | Ask | Vol. | O.I. | IV |
|---|
Boston Scientific Corporation (BSX) SEC filings: 10-K, 10-Q and 8-K
Direct links to financial reports filed with the SEC.
| Type | Date | Official link |
|---|---|---|
| 10-Q | 2026-11-02 | View filing ↗ |
| 8-K | 2026-10-28 | View filing ↗ |
| 8-K | 2026-10-07 | View filing ↗ |
| 8-K | 2026-09-23 | View filing ↗ |
| 8-K | 2026-09-08 | View filing ↗ |
| 8-K | 2026-08-26 | View filing ↗ |
| 10-Q | 2026-08-03 | View filing ↗ |
| 8-K | 2026-07-29 | View filing ↗ |
| 8-K | 2026-07-27 | View filing ↗ |
| 11-K | 2026-06-24 | View filing ↗ |
Company and Executive Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
General Information
Key Executives
| Name | Title | Age | Total pay |
|---|---|---|---|
| Mr. Michael F. Mahoney | Chairman, President & CEO | 60 | 5.73M |
| Mr. Jonathan R. Monson | Executive VP & CFO | 51 | 1.47M |
| Mr. Vance R. Brown J.D. | EVP, General Counsel & Corporate Secretary | 55 | 1.60M |
| Mr. Joseph M. Fitzgerald | Executive VP & Group President of Cardiovascular | 61 | 2.40M |
| Mr. Arthur Crosswell Butcher | Executive VP and Group President of MedSurg & Asia Pacific | 54 | 1.98M |
| Mr. Paudie O'Connor | Executive Vice President of Global Operations | 57 | - |
| Ms. Emily M. Woodworth | Senior VP, Global Controller & Chief Accounting Officer | 47 | - |
| Mr. Adam Smith | General Manager of Global Sales & Marketing | - | - |
You have seen the engine room
A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.